Kate Haviland [CNBC]
Blueprint Medicines Corporation (BPMC)
Last blueprint medicines corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
blueprintmedicines.com
Company Research
Source: CNBC
Notable in 2023: Achieving FDA approval for Blueprint's treatment of the rare disease indolent systemic mastocytosis. For years, there were no treatments designed to target indolent systemic mastocytosis in the U.S. and Europe – the most common form of a rare blood disorder that affects roughly 75,000 patients in these regions. The condition can result in debilitating symptoms ranging from joint pain to a severe, life-threatening allergic reaction. Cambridge-based biotech company Blueprint Medicines changed that in 2023 – and the breakthrough is among the biggest accomplishments for the firm's CEO Kate Haviland. Under Haviland's leadership, the U.S. Food and Drug Administration approved the company's indolent systemic mastocytosis drug, Ayvakit, in May. The agency's decision vastly expanded the reach of the treatment, which was first approved in 2021 for an advanced but less common form of the condition. When you have women and men, and people from different ethnicities or et
Show less
Read more
Impact Snapshot
Event Time:
BPMC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPMC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corporation news events
Weekly update
A roundup of the hottest topics
BPMC
News
- Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Stifel Nicolaus from $120.00 to $130.00. They now have a "buy" rating on the stock.MarketBeat
- Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $110.00 price target on the stock.MarketBeat
- Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $97.00 price target on the stock.MarketBeat
- Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $125.00 price target on the stock.MarketBeat
- Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release [Yahoo! Finance]Yahoo! Finance
BPMC
Earnings
- 2/15/24 - Beat
BPMC
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEF
- 4/25/24 - Form 8-K
- BPMC's page on the SEC website